Objective:Headache is a common disabling neurological disorder and MIGRAINE comprises more than half the causes of recurrent headaches in children. Despite extended prevalence of this type of headache there is lack of evidence about best drug treatment for MIGRAINE. So we aimed to compare the therapeutic effects of these drugs on childhood MIGRAINE.Materials d Methods:In the current study, a randomized clinical trial consisting of 78 patients according to 2004 International Headache Association criteria were randomly assigned to two groups that matched by age and sex. One of these two groups was treated with Topiramate, while the other was given Propranolol. After one and four months, the efficiency of these treatments was measured in terms of frequency, severity and duration of MIGRAINE attacks.Results:Results obtained from the data collected showed that of these 78 studied patients, 38 patients received Topiramate treatment (group A) and the rest (40 patients; group B) was treated with Propranolol. The average age of group A was 8.5±2.9 years and that of group B was 8.3±2.8 years. No significant difference was observed between these two groups in terms of reduction in frequency, severity and duration of MIGRAINE attacks.Conclusion:Results showed that both treatments had the same efficiency in healing MIGRAINE headaches and there was no significant difference between their treating results. However, further studies are needed to examine medical effects of these two medicines.

Objective: MIGRAINE is a common problem in children and the mean prevalence of MIGRAINE in Europe among 170.000 adults was 14.7% (8% in men and 17.6% in women) and in children and youth (36.000 participants), the prevalences were (9.2% for all, 5.2% in boys and 9.1% in girls) and the lifetime prevalences were (16, 11 and 20%, respectively).To determine the epidemiology of MIGRAINE and evaluate MIGRAINE triggering factors in children.Materials & Methods: Two-hundred twenty-eight children with a maximum age of 12 years who fulfilled the ICHD-II criteria for pediatric MIGRAINE were enrolled into the study.Results: This study shows that MIGRAINE is slightly more common in boys and its peak incidence is between ages 8 and 12 and most patients have three to five headache attacks per month. The pain has a tightening, stabbing or vague quality in about 70% of children with MIGRAINE and bilateral headache is slightly more common. The common triggering factors in children MIGRAINE were stress, noise, sleeplessness, hunger and light and the common relieving factors were sleep, analgesics, silence, darkness and eating.Conclusion: MIGRAINE is a common problem in children with an equal incidence in boys and girls before adolescence and more common in girls after adolescence.

Background and Aim: Patients with MIGRAINE commonly show vestibular symptoms. However, abnormal neurotological test findings during the inter-attack intervals, even in the absence of vestibular symptoms, are suggestive of subclinical vestibular dysfunction in MIGRAINE. This study aimed to compare the vestibular evoked myogenic potentials between MIGRAINE patients and normal individuals.Methods: Subjects included 25 patients with MIGRAINE and 26 healthy volunteers with an age range of 20-53 years old. The vestibular evoked myogenic potentials were recorded with 500 Hz tone bursts at 95 dB nHL.Results: Mean of absolute amplitude and p13 latency values in the MIGRAINE group were significantly less and more than the normal group, respectively (p=0.001 for absolute amplitude in right and left ears; p=0.004 for p13 latency in right ears and p=0.02 in left ears). There was no statistically significant difference between the two groups in mean of the n23 latency and also the amplitude ratio (p>0.05).Conclusion: According to the prolonged latency of vestibular evoked myogenic potentials response, vestibulospinal tract in brainstem is probably involved in MIGRAINE patients. However, due to small sample size, for generalizing this result to all patients with MIGRAINE, further researches are needed.

MIGRAINE is a paroxysmal disorder with attacks of headache, nausea, vomiting, photo- and phono phobia and malaise. MIGRAINE treatment is a mystery of medicien yet. We compare the efficacy of sodium valproate versus propranolol in our patients. Two 35 members groups with MIGRAINE headache (according to criteria of international headache society) were selected. At first, we discontinued any drugs used by subjects. In group one we started sodium valproate by dose 200 mg/day then increased it up to 600 mg/day during 3 weeks. In another group, propranolol was started 40 mg/day and was increased up to 80 mg/day in a period of 3 weeks. After 12 weeks of treatment, improvement of headache was compaired between groups. Headache severity, freqency and duration were similar in two groups after 12 weeks. It seems that propranolol and sodium valproate have the same affects on MIGRAINE headache.

Background and Aims: Psychological problems are prevalent among patients with chronic headache. A large percentage of those with MIGRAINE headache are depressed and many of them suffer from anxiety disorders. The aim of this study was assessing the personality traits in MIGRAINE patients.Materials and Methods: We randomly selected one hundred patients with MIGRAINE headaches who referred to neurology clinics. In this cross-sectional research MIGRAINE headache was diagnosed by a neurologist and recorded by IHS questionnaire. To assess personality traits, we used NEO-FFI test. Patients with a major psychiatric disorder were excluded and eighty six subjects completed the study.Results: OF all participants, 67% were female, 35% were married, and 45% high school or university graduates. The mean age was 30 years. Compared to normal population, obsessive traits were more common in MIGRAINEurs. Female had low scores in openness to experiences and male had low scores in neuroticism.Conclusion: In accordance to previous studies, we found a relationship between personality traits and MIGRAINE considering psychological profile of patients that can affect the outcome and treatment of MIGRAINE.

Background: AS epidemiologic studies show MIGRAINE is one of the most common headache syndromes in the general population. The lifetime prevalence is usually between 9% and 13%. Several psychiatric conditions are co morbid in MIGRAINE patients. Among the psychiatric illnesses, mood and anxiety disorders have been to be most strongly associated with MIGRAINE. The prevalence of MIGRAINE in people with bipolar disorder, panic disorder, generalized anxiety disorder, obsessive compulsive disorder and phobia is also elevated. This study was designed to evaluate the relationship between MIGRAINE and bipolar disorder.Methods: In a descriptive-analytical study on 213 MIGRAINE patients and 164 healthy individuals' a 15 item mood disorder questionnaire was completed. We matched group in the case of gender and age. This study was performed from March to spring 2006. The prevalence of bipolar spectrum for two groups was compared by SPSS. Findings: The prevalence of bipolar spectrum was significantly different in MIGRAINE and control group (66.5% versus 8.1%). The prevalence of bipolar spectrum was 68.4% among men who have MIGRAINE and 11% among healthy men. The prevalence of bipolar spectrum was 65.4% among women who have MIGRAINE and 5.3% among healthy women.Conclusion: The prevalence of bipolar spectrum in MIGRAINE population is more than healthy individuals. It seams that physiologic overlap between MIGRAINE and bipolar spectrum is considerable .The recognition of increased co morbidity between MIGRAINE and bipolar illness has important clinical implications and can improve treatment of these disorders.

Introduction: MIGRAINE is one of the debilitating diseases that can interfere with human function. The purpose of this study was to examine the relationship between personality and MIGRAINE headache. Materials and Methods: In this cross-sectional study, 98 patients with MIGRAINE referred to the Neurosurgical Clinic of Kosar Hospital and Semnan Specialist Neuropsychiatric Clinics in 2017 with a history of at least one year of history of the disease and 100 patients in the control group were evaluated. The instrument was a five-factor neopersonality questionnaire with questions about individual characteristics. Results: The mean± standard deviation of the age of patients with MIGRAINE was 32. 4 ± 7. 8. 53. 1% of them were male and 59. 2% of the patients were married. The mean score of emotional stability in MIGRAINE patients was significantly higher than the control group (p<0. 001), but the mean scores of enthusiasm for new experiences in MIGRAINE patients were significantly lower than the control group (p=0. 039). Notably, the score of extraversion or introversion factors (p=0. 697), consistency (p=0. 462), accountability (p=0. 056), and all questions of the questionnaire (p=0. 675) were not significant between MIGRAINE patients and control group. Conclusion: The findings showed that MIGRAINE patients are more emotionally unstable than non-MIGRAINE group, and they are less enthusiastic about their new experiences, therefore, by modifying the personality traits, it is possible to control the MIGRAINE.

Background: MIGRAINE and allergic rhinitis (AR) are two common causes of headache and facial pain in which inflammatory mediators with vasoactive function play important roles. This study aimed to determine the frequency of MIGRAINE in AR patients.Methods: In a case-control study performed from June to December 2010 in patients referred to ear, nose and throat (ENT) clinic of a university hospital in Rasht, Iran, 46 AR patients with positive skin prick tests were compared with 60 subjects without AR signs and symptoms and negative skin tests. In both groups, history of MIGRAINE was assessed according to IHS (International Headache Society) criteria. Data was analyzed by chi-square and Fisher's exact tests in SPSS17.Findings: The case group included 14 male and 32 female patients with a mean age of 31.17±8.31 years. In addition, 23 male and 37 female individuals with a mean age of 37.58±12.63 years constituted the control group. The prevalence of MIGRAINE in the case and control groups was 37% and 5%, respectively. The differences in the prevalence of MIGRAINE and MIGRAINE without aura between cases and controls were significant (P=0.001 for both conditions, odds ratio for MIGRAINE=11.244, 95% CI: 2.428-53.76). In contrast to individuals over 40 years old, in subjects younger than 30 and those between 30-39 years old, the difference in the prevalence of MIGRAINE (with and without aura) was not significant.Conclusion: The prevalence of MIGRAINE, especially without aura, in allergic patients is higher than non-allergic subjects and this correlation is more significant with increasing age.

Objectives: Conflicting results have been reported for positive effects of magnesium supplementation on MIGRAINE prophylaxis. The objective of this study was to assess whether, magnesium oxide in addition to routine treatments in adults, reduces migrainous headache frequency, MIGRAINE days and headache severity. Methods: In this 2-month clinical trial, effects of 500 mg/day oral magnesium oxide for MIGRAINE prophylaxis and serum magnesium concentration in 77 migrainous adults (case=33, control=44) aged 34.10±9.61 years, were assessed. Weight and height were measured and body mass index was calculated. Results: Significant reduction in MIGRAINEs, MIGRAINE days, headache severity and MIGRAINE index in the both groups compared with baseline, were observed. In magnesium oxide group compared with control group, 50% or greater reduction in MIGRAINEs (P<0.01) and headache severity (P<0.05) were significant. Statistically non-significant decreases in MIGRAINE index and MIGRAINE days in the magnesium oxide group were reported. Magnesium supplementation increased significantly (P<0.001) serum magnesium concentration while in control group no difference was seen. Conclusion: In spite of oral magnesium oxide supplementation (500 mg/day) in addition to routine treatments appears to be effective in MIGRAINE prophylaxis, larger trials involving this safe, appealing complementary therapy are needed.